Fig. 3

Evaluation of CDK4/6i resistant MCF7 cells. (A) MCF7 control and ribociclib resistant spheroids untreated (UT) or treated with 600 nM of ribociclib. (B) Spheroid size in control and resistant spheroids untreated (UT) or treated with 600 nM of ribociclib. (C) Proportion of living and dead cells in control and resistant spheroids untreated (UT) or treated with 600 nM of ribociclib. (D) % of apoptotic cells in untreated (UT) or treated with 600 nM of ribociclib. (E) MCF7 control and abemaciclib resistant spheroids untreated (UT) or treated with 600 nM of abemaciclib. (F) Spheroid size in control and resistant spheroids untreated (UT) or treated with 600 nM of abemaciclib. (G) Proportion of living and dead cells in control and resistant spheroids untreated (UT) or treated with 600 nM of abemaciclib. (H) % of apoptotic cells in untreated (UT) or treated with 600 nM of abemaciclib. (I) MCF7 control and palbociclib resistant spheroids untreated (UT) or treated with 600 nM of palbociclib. (J) Spheroid size in control and resistant spheroids untreated (UT) or treated with 600 nM of palbociclib. (K) Proportion of living and dead cells in control and resistant spheroids untreated (UT) or treated with 600 nM of palbociclib. (L) % of apoptotic cells in untreated (UT) or treated with 600 nM of palbociclib. All the comparative analyses were between two sets of groups: Control_UT versus R_UT and Control_T versus R_T. ‘*’- p ≤ 0.05, ‘**’- p ≤ 0.01, ‘***’- p ≤ 0.001. All figures are representative of 3 or more experiments. Error bars represent standard error of mean between experiments.